Benign Prostatic Hyperplasia
Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years.
Long-term use of the drug may predispose men to worsening erectile dysfunction and elevated risk of diabetes and non-alcoholic fatty liver disease.
PUL involves placement of small permanent metallic implants into the prostate that lift the lateral lobes away from the urethra and remove obstruction.
NSAID users had a 2-fold increased risk of BPH medication use, 59% increased risk of a recorded BPH diagnosis, and 61% increased risk for BPH surgery.
Average International Prostate Symptom Score remained low 5 years after the PVP laser procedure.
Researchers identified a predictor of new-onset UI after HoLEP that may aid urologists in clinical practice.
In a study, 81.1% of men were able to void after an average of 28 days after treatment.
In a study, 86% of prostatic urethral lift patients experienced symptom relief in the first month.
Study confirms small, but significant increases in the risks of these mental health problems among men taking the medication.
The finasteride and dutasteride recipients had significantly less mean blood loss than the placebo group.
Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.
Poor baseline functional status and having a Foley catheter preoperatively were associated with greater risk of TURP or TULIP failure.
New findings confirm previous reports.
The procedure may be particularly efficacious for men with very large prostates.
Use of 5ARIs for BPH was associated with a statistically significant increased, pooled relative risk for sexual dysfunction.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
Patients experienced a sustained decrease in AUA Symptom Score, and 95% of patients report being satisfied or very satisfied with the procedure.
Significant improvements in lower urinary tract symptoms are durable to 24 months, data show.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
New data show that the minimally invasive procedure is superior overall to TURP for treating BPH-related lower urinary tract symptoms.
Procedure partially blocks blood flow to the gland and appears to ease the need to urinate.
Three quarters of patients experienced significant improvements in lower urinary tract symptoms and quality of life observed and were satisfied with treatment.
Prostatic arterial embolization significantly reduced volumes of median lobes, central zones, peripheral zones, and whole prostate glands.
Men receiving common medical treatments for LUTS/BPH, including phytotherapy, experienced similar symptom relief.
The risk is 67% higher in men with a prostate size of 40.1-80 mL than those with smaller glands.
The risk of bladder outlet obstruction increased 34% per unit increase in serum PSA and decreased 23% per unit increase in maximal flow rate.
A recent review found little evidence to support severe lower urinary tract symptoms as a contraindication to TRT.
More adverse events seen when people undergoing interventional radiology have negative attitude.
Previous studies may have overlooked the placebo effect.
Use of high-velocity saline streams show promise in a small, first-in-man study.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Kidneys From Octogenarian Donors Show Similar Survival
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)